Who Optimizes SG&A Costs Better? Jazz Pharmaceuticals plc or Lantheus Holdings, Inc.

SG&A Cost Management: Jazz vs. Lantheus

__timestampJazz Pharmaceuticals plcLantheus Holdings, Inc.
Wednesday, January 1, 201440611400072429000
Thursday, January 1, 201544911900078634000
Friday, January 1, 201650289200075374000
Sunday, January 1, 201754415600092157000
Monday, January 1, 201868353000093326000
Tuesday, January 1, 2019736942000103132000
Wednesday, January 1, 2020854233000110171000
Friday, January 1, 20211451683000218817000
Saturday, January 1, 20221416967000233827000
Sunday, January 1, 20231343105000267194000
Loading chart...

Unleashing insights

Optimizing SG&A Costs: A Tale of Two Companies

In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Jazz Pharmaceuticals plc and Lantheus Holdings, Inc. have taken different paths in optimizing these costs over the past decade. From 2014 to 2023, Jazz Pharmaceuticals saw a significant increase in SG&A expenses, peaking in 2021 with a 258% rise from 2014. Meanwhile, Lantheus Holdings, Inc. maintained a more conservative growth, with expenses increasing by 269% over the same period.

While Jazz Pharmaceuticals' expenses surged, Lantheus Holdings, Inc. demonstrated a steadier approach, suggesting a more controlled cost management strategy. This comparison highlights the importance of strategic financial planning in the pharmaceutical industry, where every dollar saved can be reinvested into research and development, ultimately benefiting patients worldwide.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025